Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals
Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals
Status: Archived
Johns Hopkins University
mi
from
Baltimore, MD
Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals
Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals
Status: Archived
Updated: 1/1/1970
Johns Hopkins University
mi
from
Baltimore, MD
Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers
Dose-Proportionality and Intra-Individual Variability of Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate In Healthy Volunteers
Status: Archived
Johns Hopkins University
mi
from
Baltimore, MD
Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers
Dose-Proportionality and Intra-Individual Variability of Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate In Healthy Volunteers
Status: Archived
Updated: 1/1/1970
Johns Hopkins University
mi
from
Baltimore, MD
Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers
Dose-Proportionality and Intra-Individual Variability of Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate In Healthy Volunteers
Status: Archived
University of North Carolina Hospital at Chapel Hill
mi
from
Chapel Hill, NC
Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers
Dose-Proportionality and Intra-Individual Variability of Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate In Healthy Volunteers
Status: Archived
Updated: 1/1/1970
University of North Carolina Hospital at Chapel Hill
mi
from
Chapel Hill, NC
Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients
A Randomized Controlled Pilot Trial Comparing Continued Antiretroviral Therapy With Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) With Switch to Tenofovir/Emtricitabine/Raltegravir (TDF/FTC/RAL) on Changes in Endothelial Function and Markers of Bone Metabolism
Status: Archived
Indiana Univeristy School of Medicine
mi
from
Indianapolis, IN
Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients
A Randomized Controlled Pilot Trial Comparing Continued Antiretroviral Therapy With Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) With Switch to Tenofovir/Emtricitabine/Raltegravir (TDF/FTC/RAL) on Changes in Endothelial Function and Markers of Bone Metabolism
Status: Archived
Updated: 1/1/1970
Indiana Univeristy School of Medicine
mi
from
Indianapolis, IN
Addressing Psychosocial Needs and HIV Risk in Indian MSM
Addressing Psychosocial Needs and HIV Risk in Indian MSM
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Addressing Psychosocial Needs and HIV Risk in Indian MSM
Addressing Psychosocial Needs and HIV Risk in Indian MSM
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Addressing Psychosocial Needs and HIV Risk in Indian MSM
Addressing Psychosocial Needs and HIV Risk in Indian MSM
Status: Archived
Fenway Community Health Center
mi
from
Boston, MA
Addressing Psychosocial Needs and HIV Risk in Indian MSM
Addressing Psychosocial Needs and HIV Risk in Indian MSM
Status: Archived
Updated: 1/1/1970
Fenway Community Health Center
mi
from
Boston, MA
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
Status: Archived
Clinical Trial Facility
mi
from
Little Rock, AR
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Little Rock, AR
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
Status: Archived
Clinical Trial Facility
mi
from
Atlanta, GA
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Atlanta, GA
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Early Immune Responses to Vaccination - A Substudy to HVTN 205
Characterization of the Innate Immune Response to Candidate HIV Vaccines, an Ancillary Study to HVTN 205
Status: Archived
Alabama Vaccine Research Center
mi
from
Birmingham, AL
Early Immune Responses to Vaccination - A Substudy to HVTN 205
Characterization of the Innate Immune Response to Candidate HIV Vaccines, an Ancillary Study to HVTN 205
Status: Archived
Updated: 1/1/1970
Alabama Vaccine Research Center
mi
from
Birmingham, AL
Early Immune Responses to Vaccination - A Substudy to HVTN 205
Characterization of the Innate Immune Response to Candidate HIV Vaccines, an Ancillary Study to HVTN 205
Status: Archived
San Francisco Vaccine and Prevention CRS
mi
from
San Francisco, CA
Early Immune Responses to Vaccination - A Substudy to HVTN 205
Characterization of the Innate Immune Response to Candidate HIV Vaccines, an Ancillary Study to HVTN 205
Status: Archived
Updated: 1/1/1970
San Francisco Vaccine and Prevention CRS
mi
from
San Francisco, CA
Early Immune Responses to Vaccination - A Substudy to HVTN 205
Characterization of the Innate Immune Response to Candidate HIV Vaccines, an Ancillary Study to HVTN 205
Status: Archived
Fred Hutchison Center for Cancer Research
mi
from
Seattle, WA
Early Immune Responses to Vaccination - A Substudy to HVTN 205
Characterization of the Innate Immune Response to Candidate HIV Vaccines, an Ancillary Study to HVTN 205
Status: Archived
Updated: 1/1/1970
Fred Hutchison Center for Cancer Research
mi
from
Seattle, WA
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Pacific Oaks Medical Group
mi
from
Beverly Hills, CA
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Pacific Oaks Medical Group
mi
from
Beverly Hills, CA
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Providence Clinical Research
mi
from
San Fernando Valley, CA
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Providence Clinical Research
mi
from
San Fernando Valley, CA
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Peter J. Ruane, MD, Inc.
mi
from
Los Angeles, CA
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Peter J. Ruane, MD, Inc.
mi
from
Los Angeles, CA
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Washington Hospital Center
mi
from
Washington,
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Washington Hospital Center
mi
from
Washington,
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Gary Richmond, MD, PA
mi
from
Fort Lauderdale, FL
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Gary Richmond, MD, PA
mi
from
Fort Lauderdale, FL
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Orlando Immunology Center
mi
from
Orlando, FL
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Orlando Immunology Center
mi
from
Orlando, FL
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Vita Research Solutions, Inc.
mi
from
Tamarac, FL
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Vita Research Solutions, Inc.
mi
from
Tamarac, FL
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
AIDS Research Consortium of Atlanta
mi
from
Atlanta, GA
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
AIDS Research Consortium of Atlanta
mi
from
Atlanta, GA
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Northstar Medical Center
mi
from
Chicago, IL
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Northstar Medical Center
mi
from
Chicago, IL
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Albany Medical Center Hospital
mi
from
Albany, NY
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Albany Medical Center Hospital
mi
from
Albany, NY
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Aaron Diamond AIDS Research Center (ADARC)
mi
from
New York, NY
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Aaron Diamond AIDS Research Center (ADARC)
mi
from
New York, NY
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Central Texas Clinical Research
mi
from
Austin, TX
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Central Texas Clinical Research
mi
from
Austin, TX
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Therapeutic Concepts, P.A.
mi
from
Houston, TX
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Therapeutic Concepts, P.A.
mi
from
Houston, TX
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
DCH Cancer Treatment Center
mi
from
Tuscaloosa, AL
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
DCH Cancer Treatment Center
mi
from
Tuscaloosa, AL
CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery
The Impact of CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery and Gene Expression Profiles in HIV-Infected Patients With Viral Suppression
Status: Archived
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery
The Impact of CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery and Gene Expression Profiles in HIV-Infected Patients With Viral Suppression
Status: Archived
Updated: 1/1/1970
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery
The Impact of CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery and Gene Expression Profiles in HIV-Infected Patients With Viral Suppression
Status: Archived
UC San Diego Medical Center
mi
from
San Diego, CA
CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery
The Impact of CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery and Gene Expression Profiles in HIV-Infected Patients With Viral Suppression
Status: Archived
Updated: 1/1/1970
UC San Diego Medical Center
mi
from
San Diego, CA
CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery
The Impact of CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery and Gene Expression Profiles in HIV-Infected Patients With Viral Suppression
Status: Archived
Harbor UCLA Medical Center
mi
from
Torrance, CA
CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery
The Impact of CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery and Gene Expression Profiles in HIV-Infected Patients With Viral Suppression
Status: Archived
Updated: 1/1/1970
Harbor UCLA Medical Center
mi
from
Torrance, CA
Epigenetic Markers of B-Cell Function in Low Birth Weight Infants
Epigenetic Markers of B-Cell Function in Low Birth Weight Infants
Status: Archived
University of Utah
mi
from
Salt Lake City, UT
Epigenetic Markers of B-Cell Function in Low Birth Weight Infants
Epigenetic Markers of B-Cell Function in Low Birth Weight Infants
Status: Archived
Updated: 1/1/1970
University of Utah
mi
from
Salt Lake City, UT
Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers
Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers
Status: Archived
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers
Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers
Status: Archived
Updated: 1/1/1970
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)
Efficacy of CBT for Adherence and Depression in HIV Care Settings
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)
Efficacy of CBT for Adherence and Depression in HIV Care Settings
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)
Efficacy of CBT for Adherence and Depression in HIV Care Settings
Status: Archived
Fenway Community Health Center
mi
from
Boston, MA
Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)
Efficacy of CBT for Adherence and Depression in HIV Care Settings
Status: Archived
Updated: 1/1/1970
Fenway Community Health Center
mi
from
Boston, MA
Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)
Efficacy of CBT for Adherence and Depression in HIV Care Settings
Status: Archived
The Miriam Hospital Weight Control and Diabetes Research Center
mi
from
Providence, RI
Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)
Efficacy of CBT for Adherence and Depression in HIV Care Settings
Status: Archived
Updated: 1/1/1970
The Miriam Hospital Weight Control and Diabetes Research Center
mi
from
Providence, RI
Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)
Efficacy of CBT for Adherence and Depression in HIV Care Settings
Status: Archived
Butler Hospital Memory & Aging Program
mi
from
Providence, RI
Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)
Efficacy of CBT for Adherence and Depression in HIV Care Settings
Status: Archived
Updated: 1/1/1970
Butler Hospital Memory & Aging Program
mi
from
Providence, RI
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Pfizer Investigational Site
mi
from
Los Angeles, CA
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Los Angeles, CA
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Pfizer Investigational Site
mi
from
Arvada, CO
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Arvada, CO
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
PI-Coor Clinical Research, LLC
mi
from
Burke, VA
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Updated: 1/1/1970
PI-Coor Clinical Research, LLC
mi
from
Burke, VA
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Pfizer Investigational Site
mi
from
Ashland, KY
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Ashland, KY
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Darien Pediatric Associates
mi
from
Darien, CT
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Updated: 1/1/1970
Darien Pediatric Associates
mi
from
Darien, CT
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Pfizer Investigational Site
mi
from
Cape Girardeau, MO
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Cape Girardeau, MO
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Pfizer Investigational Site
mi
from
Bristol, TN
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Bristol, TN
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Pfizer Investigational Site
mi
from
Houston, TX
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Houston, TX
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
Multicenter, Randomized, Non-comparative, Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression
Status: Archived
Moores Cancer Center
mi
from
La Jolla, CA
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
Multicenter, Randomized, Non-comparative, Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression
Status: Archived
Updated: 1/1/1970
Moores Cancer Center
mi
from
La Jolla, CA
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
Multicenter, Randomized, Non-comparative, Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression
Status: Archived
Northwestern University
mi
from
Chicago, IL
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
Multicenter, Randomized, Non-comparative, Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression
Status: Archived
Updated: 1/1/1970
Northwestern University
mi
from
Chicago, IL
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
Multicenter, Randomized, Non-comparative, Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression
Status: Archived
Cornell Medical Center
mi
from
New York, NY
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
Multicenter, Randomized, Non-comparative, Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression
Status: Archived
Updated: 1/1/1970
Cornell Medical Center
mi
from
New York, NY
Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
Open Label, Randomized Trial of TDF/FTC+Raltegravir Vs. TDF/FTC+Efavirenz in HIV-1-Infected Women: Differential Effects on Viral Suppression/Reservoir, & Immune Parameters in Different Compartments, Including Gut & Genital Tract
Status: Archived
Mount Sinai Hospital
mi
from
New York, NY
Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
Open Label, Randomized Trial of TDF/FTC+Raltegravir Vs. TDF/FTC+Efavirenz in HIV-1-Infected Women: Differential Effects on Viral Suppression/Reservoir, & Immune Parameters in Different Compartments, Including Gut & Genital Tract
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
mi
from
New York, NY